Lack of KRAS and BRAF mutation in renal cell carcinoma

Eur Urol. 2009 Jun;55(6):1490-1. doi: 10.1016/j.eururo.2009.02.024. Epub 2009 Feb 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Biopsy, Needle
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / genetics*
  • Carcinoma, Renal Cell / pathology
  • Cohort Studies
  • DNA Mutational Analysis
  • ErbB Receptors / therapeutic use
  • Female
  • Follow-Up Studies
  • Gene Expression Regulation, Neoplastic
  • Genes, ras / drug effects
  • Genes, ras / genetics*
  • Humans
  • Immunohistochemistry
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / pathology
  • Male
  • Mutation*
  • Panitumumab
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins B-raf / drug effects
  • Proto-Oncogene Proteins B-raf / genetics*
  • Risk Assessment
  • Sensitivity and Specificity

Substances

  • Antibodies, Monoclonal
  • Panitumumab
  • ErbB Receptors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf